Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome

J Child Adolesc Psychopharmacol. 2006 Jun;16(3):365-70. doi: 10.1089/cap.2006.16.365.

Abstract

Atomoxetine and OROS methylphenidate were successfully used concomitantly in a 10-year-old boy suffering from attention-deficit/hyperactivity disorder (ADHD) with comorbid bipolar disorder and Tourette syndrome (TS). The child received valproic acid, clonidine, and ziprasidone concurrently. Because possible side effects of pharmacological treatment for one diagnosis may exacerbate a comorbid condition, contingent management strategies, when using polypharmacy, are mandated.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic Uptake Inhibitors / therapeutic use
  • Atomoxetine Hydrochloride
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / epidemiology
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / epidemiology
  • Central Nervous System Stimulants / therapeutic use
  • Child
  • Clonidine / therapeutic use
  • Comorbidity
  • Drug Therapy, Combination
  • Humans
  • Male
  • Methylphenidate / therapeutic use*
  • Propylamines / therapeutic use*
  • Tics / drug therapy
  • Tourette Syndrome / drug therapy*
  • Tourette Syndrome / epidemiology

Substances

  • Adrenergic Uptake Inhibitors
  • Central Nervous System Stimulants
  • Propylamines
  • Methylphenidate
  • Atomoxetine Hydrochloride
  • Clonidine